\-\ Texto\\:\\ \ \(0\)\
\-\ normal\ \(4026\)\
\-\ right\\ middle\\ and\\ posterior\\ fossa\\ mass\\ involving\\ the\\ cavernous\\ sinus\ \(0\)\
\-\ meningioma\ \(167\)\
\-\ meningioma\ \(167\)\
\-\ schwannoma\ \(67\)\
\-\ granulomatous\\ disease\ \(29\)\
\-\ lymphoma\ \(373\)\
\-\ mets\ \(38\)\
\-\ 45\\ y\\/o\\ with\\ mass\\ seen\\ on\\ ct\ \(0\)\
\-\ meningiomas\\ are\\ the\\ most\\ common\\ extra\\ axial\\ tumors\\.\\ \\ they\\ are\\ derived\\ from\\ meningothelial\\ cells\\ within\\ the\\ arachnoid\\ granulations\\.\\ \\ most\\ meningiomas\\ are\\ sporadic\\ and\\ most\\ commonly\\ occur\\ in\\ middle\\ aged\\ females\\.\\ \\ however\\,\\ multiple\\ meningiomas\\ may\\ be\\ seen\\ in\\ patients\\ with\\ nf2\\,\\ familial\\ or\\ patients\\ status\\-post\\ radiation\\.\\ \\ meningiomas\\ are\\ typically\\ divided\\ into\\ 3\\ categories\\;\\ benign\\,\\ atypical\\ meningioma\\ and\\ anaplastic\\ meningioma\\.\\ \\ most\\ meningiomas\\ are\\ found\\ supartentorial\\ which\\ accounts\\ for\\ approximately\\ 90\\ percent\\.\\ \\ the\\ cerebellopontine\\ angle\\ location\\ makes\\ up\\ less\\ than\\ 5\\ percent\\ of\\ all\\ meningiomas\\.\\ \\ imaging\\ characteristics\\ of\\ meningiomas\\ under\\ ct\\ are\\ hyper\\ to\\ isodense\\ and\\ demonstrate\\ strong\\ enhancement\\.\\ \\ many\\ will\\ show\\ calcification\\ or\\ cystic\\ areas\\ and\\ up\\ to\\ 20\\ percent\\ may\\ show\\ a\\ bony\\ change\\ such\\ as\\ hyperostosis\\.\\ \\ imaging\\ characterics\\ under\\ mr\\ are\\ isointense\\ on\\ t1\\,\\ hyperintense\\ on\\ t2\\ and\\ will\\ show\\ strong\\ enhancement\\ with\\ the\\ possibility\\ of\\ a\\ dural\\ tail\\.\\ \\ angiography\\ may\\ demonstrate\\ a\\ spoke\\ wheel\\ appearance\\ with\\ a\\ persistant\\ blush\\,\\ strong\\ early\\ uptake\\ of\\ contrast\\ and\\ will\\ persist\\ through\\ the\\ venous\\ phase\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ meningiomas\\:\\ 0\\.19642809703067293\ \(0\)\
\-\ strong\\:\\ 0\\.07302015915083\ \(0\)\
\-\ percent\\:\\ 0\\.06847993147951215\ \(0\)\
\-\ meningioma\\:\\ 0\\.06443312424421715\ \(0\)\
\-\ supartentorial\\:\\ 0\\.04321332560767891\ \(0\)\
\-\ characterics\\:\\ 0\\.04321332560767891\ \(0\)\
\-\ spoke\\:\\ 0\\.04321332560767891\ \(0\)\
\-\ are\\:\\ 0\\.03997116229268242\ \(0\)\
\-\ meningothelial\\:\\ 0\\.039815545310816436\ \(0\)\
\-\ granulations\\:\\ 0\\.039815545310816436\ \(0\)\
\-\ will\\:\\ 0\\.03931589732910503\ \(0\)\
\-\ most\\:\\ 0\\.038683041994668155\ \(0\)\
\-\ show\\:\\ 0\\.038575822566053325\ \(0\)\
\-\ under\\:\\ 0\\.03660896136256897\ \(0\)\
\-\ nf2\\:\\ 0\\.03367455036721169\ \(0\)\
\-\ persistant\\:\\ 0\\.03244261689524646\ \(0\)\
\-\ blush\\:\\ 0\\.03064004444365177\ \(0\)\
\-\ middle\\:\\ 0\\.030638813427867038\ \(0\)\
\-\ derived\\:\\ 0\\.030276770070349214\ \(0\)\
\-\ hyper\\:\\ 0\\.02993856971992298\ \(0\)\
\-\ wheel\\:\\ 0\\.02993856971992298\ \(0\)\
\-\ categories\\:\\ 0\\.02852836348241425\ \(0\)\
\-\ status\\-post\\:\\ 0\\.028289196010995464\ \(0\)\
\-\ aged\\:\\ 0\\.027634630360875254\ \(0\)\
\-\ may\\:\\ 0\\.02756365248379594\ \(0\)\
\-\ hyperostosis\\:\\ 0\\.027434522544599497\ \(0\)\
\-\ sporadic\\:\\ 0\\.02705726253903024\ \(0\)\
\-\ persist\\:\\ 0\\.02705726253903024\ \(0\)\
\-\ cerebellopontine\\:\\ 0\\.026540789423060502\ \(0\)\
\-\ isodense\\:\\ 0\\.026540789423060502\ \(0\)\
\-\ divided\\:\\ 0\\.026380054997457606\ \(0\)\
\-\ anaplastic\\:\\ 0\\.026380054997457606\ \(0\)\
\-\ accounts\\:\\ 0\\.026380054997457606\ \(0\)\
\-\ extra\\:\\ 0\\.026224424123366525\ \(0\)\
\-\ familial\\:\\ 0\\.02564705630152151\ \(0\)\
\-\ mets\\:\\ 0\\.024135775126744467\ \(0\)\
\-\ females\\:\\ 0\\.023309193203039605\ \(0\)\
\-\ makes\\:\\ 0\\.023225396961082247\ \(0\)\
\-\ tail\\:\\ 0\\.023061983136241113\ \(0\)\
\-\ up\\:\\ 0\\.02252791324562964\ \(0\)\
\-\ enhancement\\:\\ 0\\.02245577221689251\ \(0\)\
\-\ patients\\:\\ 0\\.021682103915353194\ \(0\)\
\-\ possibility\\:\\ 0\\.02115543506684428\ \(0\)\
\-\ arachnoid\\:\\ 0\\.021047695328026753\ \(0\)\
\-\ angiography\\:\\ 0\\.021047695328026753\ \(0\)\
\-\ characteristics\\:\\ 0\\.020839069767150303\ \(0\)\
\-\ isointense\\:\\ 0\\.020590185819241366\ \(0\)\
\-\ dural\\:\\ 0\\.020307301909336235\ \(0\)\
\-\ granulomatous\\:\\ 0\\.020216522263418406\ \(0\)\
\-\ 90\\:\\ 0\\.01974522882933555\ \(0\)\
\-\ phase\\:\\ 0\\.019704548423381162\ \(0\)\
\-\ angle\\:\\ 0\\.019664202839378635\ \(0\)\
\-\ imaging\\:\\ 0\\.01962817474956473\ \(0\)\
\-\ cavernous\\:\\ 0\\.019428863529641575\ \(0\)\
\-\ 45\\:\\ 0\\.019352862615249586\ \(0\)\
\-\ demonstrate\\:\\ 0\\.019278942562088633\ \(0\)\
\-\ schwannoma\\:\\ 0\\.01913168401093356\ \(0\)\
\-\ atypical\\:\\ 0\\.018154561939264485\ \(0\)\
\-\ hyperintense\\:\\ 0\\.01739049149462338\ \(0\)\
\-\ many\\:\\ 0\\.017216732921114815\ \(0\)\
\-\ fossa\\:\\ 0\\.01707254720931926\ \(0\)\
\-\ cells\\:\\ 0\\.01679630732426469\ \(0\)\
\-\ bony\\:\\ 0\\.01675174373749385\ \(0\)\
\-\ uptake\\:\\ 0\\.016642075611246136\ \(0\)\
\-\ seen\\:\\ 0\\.01655517269674206\ \(0\)\
\-\ change\\:\\ 0\\.016327066129783543\ \(0\)\
\-\ commonly\\:\\ 0\\.015806526683606086\ \(0\)\
\-\ tumors\\:\\ 0\\.015733903714071084\ \(0\)\
\-\ occur\\:\\ 0\\.015715914846968326\ \(0\)\
\-\ sinus\\:\\ 0\\.015319406713933519\ \(0\)\
\-\ early\\:\\ 0\\.015319406713933519\ \(0\)\
\-\ calcification\\:\\ 0\\.015204831463025143\ \(0\)\
\-\ venous\\:\\ 0\\.015204831463025143\ \(0\)\
\-\ they\\:\\ 0\\.015092873169055422\ \(0\)\
\-\ 20\\:\\ 0\\.015061349196848116\ \(0\)\
\-\ typically\\:\\ 0\\.014786400830911628\ \(0\)\
\-\ involving\\:\\ 0\\.014698074823545557\ \(0\)\
\-\ location\\:\\ 0\\.014611312190705357\ \(0\)\
\-\ benign\\:\\ 0\\.014456129250162751\ \(0\)\
\-\ less\\:\\ 0\\.014185980413346483\ \(0\)\
\-\ areas\\:\\ 0\\.014094839074735622\ \(0\)\
\-\ radiation\\:\\ 0\\.013746329654717336\ \(0\)\
\-\ mr\\:\\ 0\\.013309801333070755\ \(0\)\
\-\ t1\\:\\ 0\\.013276938903060018\ \(0\)\
\-\ found\\:\\ 0\\.013201105953196629\ \(0\)\
\-\ such\\:\\ 0\\.013094768577651237\ \(0\)\
\-\ approximately\\:\\ 0\\.012959891306645014\ \(0\)\
\-\ 5\\:\\ 0\\.012255688345314526\ \(0\)\
\-\ cystic\\:\\ 0\\.01208153287868509\ \(0\)\
\-\ appearance\\:\\ 0\\.011979934199679614\ \(0\)\
\-\ lymphoma\\:\\ 0\\.011971561933281792\ \(0\)\
\-\ axial\\:\\ 0\\.011954860176803292\ \(0\)\
\-\ through\\:\\ 0\\.011896848129514062\ \(0\)\
\-\ t2\\:\\ 0\\.011855827297795843\ \(0\)\
\-\ all\\:\\ 0\\.011847664163878877\ \(0\)\
\-\ ct\\:\\ 0\\.01171866326854944\ \(0\)\
\-\ however\\:\\ 0\\.011663568899985639\ \(0\)\
\-\ mass\\:\\ 0\\.011651578499485926\ \(0\)\
\-\ y\\/o\\:\\ 0\\.011601122695194317\ \(0\)\
\-\ than\\:\\ 0\\.01097572968097193\ \(0\)\
\-\ common\\:\\ 0\\.010962094176256848\ \(0\)\
\-\ on\\:\\ 0\\.010645456064197471\ \(0\)\
\-\ into\\:\\ 0\\.009967286117449544\ \(0\)\
\-\ \\;\\:\\ 0\\.009928535237512713\ \(0\)\
\-\ or\\:\\ 0\\.009818850480036348\ \(0\)\
\-\ 3\\:\\ 0\\.009808703562286959\ \(0\)\
\-\ posterior\\:\\ 0\\.009655090925012003\ \(0\)\
\-\ contrast\\:\\ 0\\.009376351405921104\ \(0\)\
\-\ multiple\\:\\ 0\\.008822578448427789\ \(0\)\
\-\ within\\:\\ 0\\.007990840237186674\ \(0\)\
\-\ which\\:\\ 0\\.007819336211973277\ \(0\)\
\-\ a\\:\\ 0\\.007776466702325515\ \(0\)\
\-\ disease\\:\\ 0\\.006846752653018157\ \(0\)\
\-\ \\,\\:\\ 0\\.00663505062542371\ \(0\)\
\-\ normal\\:\\ 0\\.006566727718623044\ \(0\)\
\-\ be\\:\\ 0\\.0064595917810976915\ \(0\)\
\-\ as\\:\\ 0\\.0063361642445790576\ \(0\)\
\-\ from\\:\\ 0\\.006208018201736335\ \(0\)\
\-\ and\\:\\ 0\\.006176779608458477\ \(0\)\
\-\ right\\:\\ 0\\.004419763279953023\ \(0\)\
\-\ to\\:\\ 0\\.00418694223963712\ \(0\)\
\-\ in\\:\\ 0\\.004131345393531911\ \(0\)\
\-\ the\\:\\ 0\\.004066155432459582\ \(0\)\
\-\ for\\:\\ 0\\.003574059552170172\ \(0\)\
\-\ with\\:\\ 0\\.0022941995311743083\ \(0\)\
\-\ of\\:\\ 0\\.0022843882509409495\ \(0\)\
\-\ \\.\\:\\ 0\\.0019141906719157306\ \(0\)\
